Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma : Episode 5

News

Video

November 21, 2023

Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

Author(s):

Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.

EP: 1.Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

EP: 2.Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

EP: 3.Imaging and Staging Considerations in Renal Cell Carcinoma

EP: 4.Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

Now Viewing

EP: 5.Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

EP: 6.Comparing Treatment Combinations in Renal Cell Carcinoma

EP: 7.Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

EP: 8.Sequencing and Second-Line Therapy in RCC: Patient Scenario

EP: 9.Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

EP: 10.Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

EP: 11.Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

EP: 12.Triple Combination Therapies in RCC: Clinical Trial Insights

EP: 13.Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

Related Content

November 9th 2024

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com

November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

November 1st 2024

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

October 31st 2024

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC